cladribine has been researched along with Lymphopenia in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 10 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aldridge, J; Coyle, PK; Galazka, A; Giovannoni, G; Leist, TP; Lemieux, C; Nolting, A; Vermersch, P; Walker, B | 1 |
| Aslan, D; Hackert, J; Hagenacker, T; Huntemann, N; Kleinschnitz, C; Kleinschnitz, K; Meuth, SG; Pawlitzki, M; Pfeuffer, S; Pul, R; Rolfes, L; Ruck, T; Schmidt, M; Skuljec, J; Su, C | 1 |
| Assefi, A; D'Eramo, M; Etchepare, A; Grinspan, A; Iut, VC; Negrotto, L | 1 |
| Ferrè, L; Filippi, M; Martinelli, V; Meani, A; Moiola, L; Rocca, MA; Zanetta, C | 1 |
| Adamczyk-Sowa, M; Bartosik-Psujek, H; Chorąży, M; Jamróz-Wiśniewska, A; Kurkowska-Jastrzębska, I; Kułakowska, A; Piasecka-Stryczyńska, K; Pogoda-Wesołowska, A; Puz, P; Rejdak, K; Stępień, A; Słowik, A; Tokarz-Kupczyk, E | 1 |
| Alexandri, N; Brieva, L; Brochet, B; Hupperts, R; Keller, B; Kubala Havrdova, E; Langdon, D; Lechner-Scott, J; Maida, EM; Montalban, X; Nolting, A; Patti, F; Piehl, F; Selmaj, K; Smyk, A; Solari, A | 1 |
| Amor, S; Baker, D; Giovannoni, G; Kang, AS; Schmierer, K | 1 |
| Berger, B; Dersch, R; Engelhardt, M; Fähndrich, S; Rauer, S; Wehrum, T | 1 |
| Brownlee, WJ | 1 |
| Ahmad, B; Gummi, R; Walsh, RD | 1 |
| Adeniji, AK; Comi, G; Cook, S; Dangond, F; Giovannoni, G; Rammohan, K; Rieckmann, P; Soelberg Sorensen, P; Vermersch, P | 1 |
| Ammoscato, F; Baker, D; Ceronie, B; Dubuisson, N; Giovannoni, G; Jacobs, BM; Lock, H; Longhurst, HJ; Mao, Z; Schmierer, K | 1 |
| Dangond, F; Hicking, C; Munafo, A; Terranova, N | 1 |
| Deeks, ED | 1 |
| Comi, G; Cook, S; Galazka, A; Giovannoni, G; Hicking, C; Leist, T; Montalban, X; Nolting, A; Sylvester, E | 1 |
| Comi, G; Cook, S; Dangond, F; Galazka, A; Giovannoni, G; Hicking, C; Nolting, A; Rieckmann, P; Sørensen, PS; Vermersch, P | 1 |
| Chang, P; Comi, G; Cook, S; Giovannoni, G; Greenberg, SJ; Hamlett, A; Musch, B; Rammohan, K; Rieckmann, P; Soelberg Sørensen, P; Vermersch, P | 1 |
| Schmidt, S | 1 |
| Comi, G; Cook, S; Giovannoni, G; Greenberg, SJ; Hamlett, A; Miret, M; Musch, B; Rammohan, K; Rieckmann, P; Sørensen, PS; Vermersch, P; Viglietta, V; Weiner, J | 1 |
| Dinçol, G; Kahraman, R | 1 |
| Burris, HA; Eckardt, JR; Fields, S; Kuhn, JG; Rizzo, J; Rodriguez, GI; Smith, LS; VanDenBerg, K; von Hoff, DD; Weiss, GR | 1 |
| Aractingi, S; Bastie, JN; Castaigne, S; Chosidow, O; Meunier, P | 1 |
| Cavallin-Ståhl, E; Juliusson, G; Liliemark, J; Martinsson, U; Porwit, A; Strömberg, M; Svedmyr, E | 1 |
| Delannoy, A; Devogelaer, JP; Houssiau, FA | 1 |
| Bocchia, M; Lauria, F; Marotta, G; Raspadori, D; Rondelli, D; Zinzani, PL | 1 |
3 review(s) available for cladribine and Lymphopenia
| Article | Year |
|---|---|
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Betacoronavirus; CD8-Positive T-Lymphocytes; Cladribine; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Deprescriptions; Dimethyl Fumarate; Fingolimod Hydrochloride; Glatiramer Acetate; Hematopoietic Stem Cell Transplantation; Humans; Hydroxybutyrates; Immune Evasion; Immunity, Innate; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Lymphopenia; Macrophages; Monocytes; Multiple Sclerosis; Natalizumab; Nitriles; Pandemics; Pneumonia, Viral; Respiratory Distress Syndrome; SARS-CoV-2; Toluidines | 2020 |
Cladribine Tablets: A Review in Relapsing MS.
Topics: Cladribine; Drug Interactions; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Tablets | 2018 |
[Oral cladribine for relapsing-remitting multiple sclerosis: another purine analogue or a genuine therapeutic innovation?].
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Animals; Azathioprine; Cladribine; Clinical Trials, Phase III as Topic; Disability Evaluation; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents; Infusions, Intravenous; Long-Term Care; Lymphopenia; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neoplasms; Pregnancy; Purine Nucleosides; Randomized Controlled Trials as Topic; Thrombocytopenia | 2010 |
7 trial(s) available for cladribine and Lymphopenia
| Article | Year |
|---|---|
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Topics: Adult; Cladribine; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Longitudinal Studies; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2018 |
Effects of Postponing Treatment in the Second Year of Cladribine Administration: Clinical Trial Simulation Analysis of Absolute Lymphocyte Counts and Relapse Rate in Patients with Relapsing-Remitting Multiple Sclerosis.
Topics: Administration, Oral; Algorithms; Cladribine; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphopenia; Male; Multiple Sclerosis, Relapsing-Remitting; Practice Guidelines as Topic; Recurrence; Time Factors; Time-to-Treatment | 2019 |
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Analysis of Variance; Brain; Cladribine; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Intention to Treat Analysis; Lymphopenia; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2010 |
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Topics: Administration, Oral; Adult; Cladribine; Disability Evaluation; Double-Blind Method; Europe; Herpes Zoster; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neoplasms; Neurologic Examination; Physical Examination; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United States; Young Adult | 2011 |
A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.
Topics: Adult; Aged; Agranulocytosis; Anemia; Cell Count; Chromatography, High Pressure Liquid; Cladribine; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lymphopenia; Male; Middle Aged; Neoplasms; Neutrophils; Thrombocytopenia | 1995 |
Cladribine for untreated or early low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Transformation, Neoplastic; Cladribine; Disease Progression; Female; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Lymphopenia; Male; Middle Aged; Platelet Count; Survival Analysis; Thrombocytopenia; Treatment Outcome | 1998 |
Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cladribine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infection Control; Interferon-alpha; Leukemia, Hairy Cell; Lymphopenia; Male; Middle Aged; Neutropenia; Pentostatin; Remission Induction; Treatment Outcome | 1999 |
15 other study(ies) available for cladribine and Lymphopenia
| Article | Year |
|---|---|
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
Topics: Adolescent; Adult; Age Factors; Aged; Cladribine; Humans; Infections; Lymphocyte Count; Lymphopenia; Middle Aged; Multiple Sclerosis; Tablets; Young Adult | 2021 |
Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
Topics: CD8-Positive T-Lymphocytes; Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recurrence | 2022 |
High persistence and low adverse events burden in cladribine treated MS patients from Argentina.
Topics: Adult; Argentina; Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Tablets | 2022 |
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational study.
Topics: Cladribine; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Recurrence | 2023 |
Cladribine tablets for highly active relapsing-remitting multiple sclerosis in Poland: a real-world, multi-centre, retrospective, cohort study during the COVID-19 pandemic.
Topics: Adult; Cladribine; Cohort Studies; COVID-19; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Poland; Retrospective Studies; Tablets | 2023 |
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
Topics: Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Quality of Life; Tablets | 2023 |
COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Topics: Betacoronavirus; Cladribine; Coronavirus Infections; COVID-19; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index | 2020 |
COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
Topics: Betacoronavirus; Cladribine; Coronavirus Infections; COVID-19; Humans; Lymphopenia; Multiple Sclerosis; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
Topics: Cladribine; Humans; Immunosuppressive Agents; Lymphopenia; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting | 2021 |
Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells.
Topics: Administration, Oral; Adult; Alemtuzumab; Apoptosis; B-Lymphocyte Subsets; Cladribine; Cross-Sectional Studies; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Female; Humans; Immunologic Factors; Lymph Nodes; Lymphopenia; Male; Multiple Sclerosis; RNA, Messenger; Treatment Outcome | 2018 |
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Herpes Zoster; Humans; Immunosuppressive Agents; Lymphopenia; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Registries; Young Adult | 2019 |
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
Topics: Adolescent; Adult; Aged; Cladribine; Clinical Trials, Phase III as Topic; Cohort Studies; Humans; Immunosuppressive Agents; Lymphocyte Count; Lymphocytes; Lymphopenia; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Randomized Controlled Trials as Topic; Registries; Tablets; Young Adult | 2019 |
Cryptococcus neoformans meningitis in a patient with hairy cell leukemia.
Topics: Adult; Antineoplastic Agents; Cladribine; Cryptococcus neoformans; Humans; Leukemia, Hairy Cell; Lymphopenia; Male; Meningitis, Cryptococcal; Opportunistic Infections; Treatment Outcome | 2006 |
Cutaneous reactions after treatment with 2-chlorodeoxyadenosine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CD4-Positive T-Lymphocytes; Cladribine; Drug Eruptions; Female; Humans; Leukemia, Hairy Cell; Lymphopenia; Male; Middle Aged; Retrospective Studies | 1996 |
Paradoxical immunologic effects of 2-CdA therapy: comment on the article by Davis et al.
Topics: Anemia, Hemolytic; Antibodies, Antinuclear; Arthritis, Rheumatoid; Cladribine; Female; Humans; Immune System Diseases; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lupus Nephritis; Lymphopenia; Male; Middle Aged | 1998 |